Authors

Latest:

Dr. Elias on Androgen Receptor Inhibitors in HER2-Positive Breast Cancer

Anthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado School of Medicine, discusses using androgen receptor inhibitors as a potential treatment of patients with HER2-positive breast cancer.

Anthony El-Khoueiry, MD

Latest:

Importance of Real-World Data in Supporting Treatment Options

Panelists discuss the insights from real-world data on the effectiveness of cabozantinib, regorafenib, and ramucirumab in second-line treatment for unresectable hepatocellular carcinoma, highlighting the differences between strict eligibility criteria and more flexible modified criteria in patient selection.

Anthony El-Khoueiry, MD, USC Norris Comprehensive Cancer Center

Latest:

Drs El-Khoueiry and Hughes-Halbert on the Importance of a Multidisciplinary Approach in Cancer Care

Anthony B. El-Khoueiry, MD, and Chanita Hughes-Halbert, PhD, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.

Anthony El-Khoueiry, MD, USC Keck School of Medicine

Anthony Faber, PhD, Madhu Gowda, MD

Latest:

BCL-2 Inhibitors May Provide Avenue of Attack Against High-Risk Neuroblastoma

Investigators at Virginia Commonwealth University Massey Cancer Center discuss the current treatment for children with high-risk neuroblastoma including high-dose chemotherapy, surgery, stem cell transplantation, radiation therapy, isotretinoin, and immunotherapy.

Anthony Hagen

Latest:

CMS Unveils Proposed Radiation Oncology Model of Care

Until now, radiation oncology (RO) has remained largely untouched by the valuebased initiatives of the Centers for Medicare and Medicaid Services. The federal agency aims to change that with a proposed RO Model of care that would promote site-neutral payment and take away incentives for volume-based billing.

Anthony J. Cmelak, MD

Latest:

Dr. Cmelak Discusses the Results of the ECOG1308 Study

Anthony J. Cmelak, MD, professor, Radiation Oncology, Vanderbilt-Ingram Cancer Center, discusses the results of ECOG1308, a study that evaluated reduced-dose IMRT in HPV-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response to induction chemotherapy.

Anthony J. Olszanski, MD, RPh

Latest:

Dr. Olszanski Discusses Advances in Stage III Melanoma

Anthony J. Olszanski, MD, RPh, vice chair, Department of Hematology/Oncology, director, Early Drug Development Phase I Program, Fox Chase Cancer Center, discusses treatment advances in stage III melanoma.

Anthony M. Magliocco, MD

Latest:

Dr. Magliocco on Analyzing the Genome of Melanoma Tumors

Anthony M. Magliocco, MD, chair of pathology, executive director of esoteric labs at Moffitt Cancer Center, discusses the difficulties of analyzing the genome of melanoma tumors.

Anthony Mato, MD

Latest:

Dr. Mato on the Potential Use of Noncovalent BTK Inhibitors in CLL

Anthony Mato, MD, MSCE, discusses recent data on the emerging class of noncovalent BTK inhibitors in chronic lymphocytic leukemia and their potential advantage over currently approved covalent BTK inhibitors.

Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center

Latest:

The Future of the Treatment Landscape in MZL and FL

Key opinion leaders in hematology-oncology consider the future treatment landscape for marginal zone and follicular lymphomas and reflect on the role of chemotherapy and targeted agents as induction or maintenance.

Anthony P. Conley, MD, The University of Texas MD Anderson Cancer CenterSyma Iqbal, MD, UCS Norris Comprehensive Cancer Center

Anthony P. Conley, MD, University of Texas MD Anderson Cancer Center

Anthony R. Mato, MD

Latest:

Noncovalent BTK Inhibitors in CLL

Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.

Anthony R Mato, MD, Memorial Sloan Kettering Cancer Center

Anthony R. Mato, MD, MSCE

Latest:

Pirtobrutinib and Other Non-Covalent BTK Inhibitors in the Treatment of CLL

The assembled faculty comment on data on the role of non-covalent BTK inhibitors in the CLL treatment landscape, with emphasis on the phase 1/2 BRUIN trial of pirtobrutinib.

Anthony R. Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center

Anthony S. Stein, MD

Latest:

Dr. Stein on Blinatumomab for Relapsed/Refractory ALL

Anthony S. Stein, MD, professor and staff physician, Hematologic Malignancies and Stem Cell Transplantation Institute, City of Hope, discusses a phase II study examining blinatumomab in relapsed/refractory patients with Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.

Anthony S. Stein, MD, Hematologic Malignancies

Anthony Shields, MD, PhD

Latest:

Dr. Shields on the Standard of Care in Newly Diagnosed mCRC

Anthony Shields, MD, PhD, oncologist, Department of Oncology, Molecular Imaging and Diagnostics Program, Barbara Ann Karmanos Cancer Institute, discusses the standard of care in patients with newly diagnosed metastatic colorectal cancer (mCRC).